Shots:

• The approval is based on P-III POLYP 1 & 2 trials assessing Xolair vs PBO in 138 & 127 adult patients with nasal polyps who had an inadequate response to nasal corticosteroids respectively
• Results: @24wks. improvement in NPS (-1.1 vs 0.1 & -0.9 vs -0.3); improvement in NCS (-0.9 vs -0.4 & -0.7 vs -0.2); no new or unexpected safety signals were identified respectively
• Xolair is the first biologic for the treatment of nasal polyps that targets and blocks IgE. In the US- Novartis & Genentech work together to develop and co-promote Xolair

Source1- Source2 ­ 

Ref: Genentech & Novartis | Image: Novartis